{"nctId":"NCT04036292","briefTitle":"Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease","startDateStruct":{"date":"2019-07-23","type":"ACTUAL"},"conditions":["Dry Eye Disease (DED)"],"count":758,"armGroups":[{"label":"OC-01 Low Dose, 0.6 mg/mL","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: OC-01 (varenicline) nasal spray"]},{"label":"OC-01 High Dose, 1.2 mg/mL","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: OC-01 (varenicline) nasal spray"]},{"label":"Placebo (vehicle) nasal spray","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (vehicle) nasal spray"]}],"interventions":[{"name":"OC-01 (varenicline) nasal spray","otherNames":[]},{"name":"Placebo (vehicle) nasal spray","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 6 months prior to Visit 1\n\nExclusion Criteria:\n\n* Have had any intraocular surgery (such as cataract surgery) or extraocular surgery in either eye within three months or refractive surgery (e.g. laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within twelve months of Visit 1.\n* Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with dry eye disease are allowed.\n* Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)\n* Have a known hypersensitivity to any of the procedural agents or study drug components\n* Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject.","healthyVolunteers":false,"sex":"ALL","minimumAge":"22 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28)","description":"The primary endpoint was the percentage of subjects who achieve ≥10 mm improvement in Schirmer's Test Score from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test scores from 0-35 mm where a higher score is indicative of a better outcome.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Eye Dryness Score in CAE at Week 4 at 5 Minutes","description":"Change in Eye Dryness Score Eye from baseline in CAE at 4 Weeks at 5 minutes post treatment. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.3","spread":"1.62"},{"groupId":"OG001","value":"-9.0","spread":"1.75"},{"groupId":"OG002","value":"-7.4","spread":"1.74"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Eye Dryness Score From Baseline to Day 28","description":"Change in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.8","spread":"1.54"},{"groupId":"OG001","value":"-22.2","spread":"1.61"},{"groupId":"OG002","value":"-15.4","spread":"1.57"}]}]}]},{"type":"SECONDARY","title":"Mean Change Form Baseline in Schirmer's Test Score From Baseline to Day 28","description":"Change in Schirmer test score from baseline to Day 28. Schirmer's test scores from 0-35 mm where a higher score is indicative of a better outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":"0.61"},{"groupId":"OG001","value":"11.5","spread":"0.64"},{"groupId":"OG002","value":"6.3","spread":"0.61"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 2","description":"Chang in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better otucome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.5","spread":"1.38"},{"groupId":"OG001","value":"-17.9","spread":"1.45"},{"groupId":"OG002","value":"-12.7","spread":"1.41"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Eye Dryness Score in the Study Eye at Week 1","description":"Change in Eye Dryness Score Eye from baseline to 28 days. Eye dryness score on a Visual Analogue Scale (VAS) from 0 (no dryness) to 100 (maximum dryness) millimeters where a lower score is indicative of a better outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.7","spread":"1.33"},{"groupId":"OG001","value":"-15.4","spread":"1.40"},{"groupId":"OG002","value":"-13.3","spread":"1.35"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":260},"commonTop":["Sneezing","Cough","Throat irritation","Instillation site irritation","Nasopharyngitis"]}}}